Review

built-in function within (TriNetX Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

TriNetX Inc built-in function within
Built In Function Within, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trinetx+built-in+function/built+in+function/pmc11393353-110-6-14
Average 90 stars, based on 1 article reviews

built-in function within - by Bioz Stars, 2026-11

90/100 stars

Images

Clinical Proteomics:

Article Title: Olfactory and Gustatory Disturbances as Early Indicators of Lung Cancer in Patients with Sleep Disorders: A Retrospective Cohort Study from the TriNetX US Collaborative Networks
Article Snippet: Utilizing the built-in functionality of TriNetX, we matched the two groups at a 1:1 ratio, considering factors such as age, race, gender, comorbidities, medication use, and laboratory data.

Article Title: Outcomes of Outpatient Elective Esophageal Varices Band Ligation in Cirrhosis Patients with Significant Thrombocytopenia.
Article Snippet: TriNetX’s built-in function was used to match the two groups at a 1:1 ratio by nearest neighbor, matching for age at index, hypertension, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), malignancy, heart failure, ascites, SBP, PPI use, Child–Pugh, and MELD variables.

Article Title: Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study
Article Snippet: All statistical analyses were conducted using the built-in functions from the TriNetX platform.

Article Title: Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.
Article Snippet: Background: Immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE).. Glucagon-like peptide-1 agonists (GLP1a), initially developed for type 2 diabetes mellitus (T2DM), have shown promising results in reducing cardiovascular events.. We aimed to investigate the effect of GLP1a on cardiovascular events in patients receiving ICIs.

Article Title: The trends and outcomes of inflammatory bowel disease surgery during the COVID‐19 pandemic: A retrospective propensity score‐matched analysis from a multi‐institutional research network
Article Snippet: TriNetX's built‐in function facilitated matching based on age at index, gender, ethnicity, and comorbidities such as obesity, diabetes mellitus, hypertension, ischemic heart disease, chronic kidney disease, nicotine dependence, and chronic lower respiratory diseases.

Article Title: Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study.
Article Snippet: All statistical analyses were conducted using the built- in functions from the TriNetX platform.

Article Title: Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
Article Snippet: The TriNetX dataset's built‐in function was used, employing greedy nearest‐neighbor matching based on age, sex, race, comorbidities, medication, and laboratory data.

Review

built-in function within (TriNetX Inc)

Structured Review

Images

Related Articles

Clinical Proteomics:

Similar Products

Image Search Results